Capture Vascular | October 2013: Capture Expands Board of Directors
2694
single,single-post,postid-2694,single-format-standard,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

October 2013: Capture Expands Board of Directors

October 2013: Capture Expands Board of Directors

Capture Vascular announced today that the Company has added Neil Desai, Ph.D. and Jack Springer to their Board of Directors, expanding the total number of directors to four.

Neil Desai, Ph.D. is currently the V.P. of Strategic Platforms at Celgene Corporation. Prior to its acquisition by Celgene, he was Senior VP of Global R&D at Abraxis Bioscience (ABI), where he developed the company’s product pipeline and intellectual property portfolio. Desai is an inventor of ABI’s nanotechnology and nanoparticle albumin bound (nab®) drug delivery platform, was primarily responsible for the development of its nanotechnology drug, Abraxane® and discovery of the novel targeted biological pathways utilized by nab®-drugs. Abraxis was acquired by Celgene in 2010 for approximately $3 billion.  He was one of the first few members of ABI’s predecessor companies, VivoRx, Inc and VivoRx Pharmaceuticals, Inc., where he held positions of increasing responsibility since 1991.  Neil is also the founder and CEO of AADi, LLC, a clinical stage company developing a nanotechnology therapeutic in the oncology and cardiovascular fields. He serves on the Board of Directors and as advisor to a number of start-up companies.

He has more than 20 years of experience in R&D of novel nanotechnology based drug delivery systems with over 100 issued patents, over 40 peer-reviewed publications and book chapters, and over 200 presentations at scientific meetings.  Dr. Desai holds a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India and a M.S. and Ph.D. in Chemical Engineering from the University of Texas at Austin.

Jack Springer has spent the last 25 years in medical devices and diagnostics.  Since 2011, Jack has consulted with many device companies and currently serves on the boards of Vatrix Medical and Aneurysm Diagnostic.  Prior to starting his consulting practice, Jack was head of the U.S. business for Invatec when they were acquired by Medtronic, Inc. for $500M in April of 2010.  Post-acquisition he led the integration of the U.S. business as the V.P. of Commercial Operations and Brand Marketing. His career started out in sales and marketing at Abbott Laboratories where he won numerous awards for sales performance.  He then moved to Cordis Corporation, a Division of Johnson and Johnson, where he initially took on sales training and development roles and subsequent sales management and marketing positions.  He was promoted to Global General Manager in 2003 and served in that role until April of 2006.

During his 12 year tenure at Cordis, the business unit grew at an annual rate of over 25% per year reaching sales of over $550M.   Cordis Endovascular has been recognized as one of the most successful cardiovascular device companies during this period. He drove the development and introduction of several major products that changed how physicians treat peripheral vascular disease.   He also holds significant experience in developing businesses outside the U.S. in both Asia Pacific and Europe.  Mr. Springer received his BA degree from McDaniel College in Westminster, Md. and has completed additional course work at the University of Michigan Business School.  He also earned a commission in the U.S. Army and served four years on active duty before moving into healthcare.

No Comments

Sorry, the comment form is closed at this time.